Alumis Reports Phase III Wins for Oral Psoriasis Pill, Analysts Unmoved
Alumis posted a set of Phase III wins for its oral psoriasis pill, yet analysts remain lukewarm on the program's commercial impact in a crowded field.
Topic
Oral Therapy
Topic
Oral Therapy
89% of Psoriasis Patients on J&J Pill Report Clear Genital Skin at Two Years
Two-year data for J&J's oral psoriasis therapy show 89% of patients achieved clear skin in previously affected genital areas, add…
EMA Backs First Oral IL-23 Receptor Agent for Plaque Psoriasis
The EMA's CHMP has adopted a positive opinion for the first oral IL-23 receptor-targeted therapy for plaque psoriasis, setting up…
FDA Approves Icotrokinra, First Targeted Oral Peptide for Plaque Psoriasis
FDA approves icotrokinra, the first targeted oral peptide for moderate-to-severe plaque psoriasis, expanding systemic options bey…
Newly Approved Oral Psoriasis Therapy Expands Treatment Options
Regulators have approved a new oral psoriasis therapy, adding a pill-based systemic option to the plaque psoriasis armamentarium.…
FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis
The FDA has approved icotrokinra, the first oral IL-23 receptor antagonist for psoriasis, giving dermatologists a tablet-based op…
Zasocitinib Clears Psoriasis at Hardest-to-Treat Sites in Once-Daily Pill
Once-daily oral TYK2 inhibitor zasocitinib cleared psoriasis at the scalp, palms, soles and nails — sites where topicals and curr…
FDA Approves Oral Psoriasis Pill Developed with UQ Research
The FDA has approved an oral psoriasis pill that University of Queensland researchers call "life-changing," offering patients a s…